ALLEGAN, Mich., March 21, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic Goods Administration permitting the Company to sell generic temozolomide in Australia. The letter also states that bioequivalence was met between the brand product, Temodar®, and the Company's generic temozolomide, enabling listing on the Pharmaceutical Benefits Scheme or PBS.
(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )
Perrigo's product is the generic equivalent to Schering-Plough's Temodar®, indicated for patients with malignant glioma, where the product is currently generating over $20 million in sales in Australia. Glioma is the most common primary malignant brain tumor in adults, responsible for 75% of adult primary malignant brain tumors. Perrigo's product provides a quality alternative, making cancer therapy more cost effective for the Australians that suffer from glioma.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval is an excellent example of the Company's geographic diversification and international capabilities. We look forward to providing this quality, affordable product to the people of Australia."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Perrigo Company
CONTACT: Arthur J. Shannon, Vice President, Investor Relations and Communication, +1-269-686-1709, firstname.lastname@example.org, or Bradley Joseph, Senior Manager, Investor Relations and Communication, +1-269-686-3373, email@example.com
Web Site: http://www.perrigo.com